AEF0117: A Novel Signaling-Specific CB1 Inhibitor for Cannabis Use Disorder Treatment
Explore the groundbreaking potential of AEF0117, a new class of drug offering a novel approach to treating Cannabis Use Disorder.
Get a Quote & SampleProduct Core Value
AEF0117
AEF0117 represents a significant advancement in the treatment of Cannabis Use Disorder (CUD), functioning as the first Signaling-Specific Inhibitor (CB1-SSi) of the cannabinoid receptor 1 (CB1). This innovative compound selectively targets and inhibits a subset of intracellular effects resulting from THC binding without altering behavior itself. Its development has been rigorously tested through preclinical and clinical trials, demonstrating a strong safety profile and promising efficacy in reducing the negative impacts associated with cannabis use.
- Discover how AEF0117 is revolutionizing the pharmacological treatment of cannabis use disorder, offering a new hope for individuals struggling with addiction.
- Understand the unique mechanism of action of CB1-SSi, differentiating AEF0117 from traditional CB1 receptor antagonists and their associated adverse effects.
- Learn about the preclinical efficacy and safety data that paved the way for human trials, showcasing AEF0117's potential as a non-addictive therapeutic agent.
- Explore the findings from Phase 1 and Phase 2a clinical trials, highlighting AEF0117's well-tolerated safety profile and its significant impact on reducing cannabis self-administration and subjective effects.
Key Advantages of AEF0117
Targeted Mechanism
AEF0117 provides a targeted approach by selectively inhibiting specific CB1 receptor signaling pathways, minimizing off-target effects and improving patient safety compared to broader receptor antagonists.
Improved Safety Profile
Clinical trials have established AEF0117 as safe and well-tolerated, without precipitating withdrawal symptoms, making it a promising option for long-term CUD management.
Reduced Cannabis Effects
Studies show AEF0117 effectively reduces the subjective positive effects and self-administration of cannabis, offering a novel strategy for managing addiction.
Key Applications
Cannabis Use Disorder Treatment
AEF0117 offers a new pharmacological treatment for individuals struggling with Cannabis Use Disorder, aiming to reduce cravings and dependence.
Addiction Management
As a novel non-addictive cannabinoid receptor modulator, AEF0117 presents a unique therapeutic avenue for managing various forms of addiction by targeting the CB1 receptor.
Neurological Disorder Research
The research into AEF0117's mechanism provides valuable insights into the endocannabinoid system and its role in brain diseases, potentially opening doors for future neurological treatments.
Harm Reduction Strategies
By mitigating the negative subjective effects of THC, AEF0117 can contribute to harm reduction strategies related to cannabis use.